We describe two patients who developed respiratory syncytial virus (RSV) pneumonia after BMT. One died of RSV pneumonia after three courses of steroid pulse therapy. Surprisingly, RSV antigen was identified in the bronchoalveolar lavage fluid (BALF) obtained post mortem. Steroid pulse therapy might have suppressed anti-RSV immunity, leading to persistent RSV infection for more than 1 month. The other patient received donor lymphocyte infusions (DLI) for relapsed plasma cell leukemia, while having active RSV pneumonia. His respiratory condition improved after DLI, and RSV antigen disappeared in BALF and nasal swabs. DLI might be effective in cases of life-threatening RSV pneumonia. Bone Marrow Transplantation (2000) 26, 573-576. Keywords: respiratory syncytial virus; donor lymphocyte infusion; steroid pulse therapy; bone marrow transplantation; interstitial pneumonia Nosocomial transmission of respiratory syncytial virus (RSV) is a serious problem in immunocompromised patients, and they can acquire infection following BMT from either infected family members or hospital employees. The incidence of RSV infection after BMT is also as high as 7.7%.
Nosocomial transmission of respiratory syncytial virus (RSV) is a serious problem in immunocompromised patients, and they can acquire infection following BMT from either infected family members or hospital employees. The incidence of RSV infection after BMT is also as high as 7.7%. 1 In contrast to healthy individuals, progression to pneumonia is rapid in these patients. Although the majority of RSV infections are self-limiting in healthy adults, approximately half of the patients who become infected with RSV will develop pneumonia with an associated high mortality. 2 We describe two patients who developed interstitial pneumonia (IP) caused by RSV. Both patients received steroid pulse therapy for IP, and one patient underwent donor lymphocyte infusions (DLI) from his donor for relapsed plasma cell leukemia (PCL). Both steroid pulse therapy and DLI seemed to affect the course of RSV infection in these patients. This experience may provide some important information on the pathogenesis and treatment of RSV infection following BMT.
Case 1
A 54-year-old man diagnosed with CML underwent BMT from his HLA-identical sister in September 1999. The conditioning regimen was BU/CY, and the GVHD prophylaxis consisted of cyclosporine and short-term methotrexate. His clinical course had been uneventful.
He complained of rhinorrhea and cough on day 68, followed by the development of dyspnea on day 73. His arterial oxygen saturation decreased to 84%. CT scans of the chest showed marked central bronchial wall thickening and multiple patchy densities along the bronchovascular bundles ( Figure 1) . He was diagnosed with IP based upon these findings. We initiated intravenous immunoglobulin and steroid pulse therapy consisting of 1 g/day of methylprednisolone for 3 consecutive days. He responded to the steroid pulse therapy (Figure 2 ), and we repeated two more courses of the steroid pulse therapy until day 87. However, the response was transient. Despite the intensive immunosuppression, respiratory failure progressed rapidly ( Figure  3 ) and he died of respiratory failure on day 103. We obtained bronchoalveolar lavage fluid (BALF), from which RSV antigen and RSV-specific mRNA were detected by EIA 3 and RT-PCR. 4 He was finally diagnosed with RSV IP.
Case 2
A 52-year-old man with PCL in second remission underwent BMT from his HLA-identical sibling in November 1998. Extramedullary relapse occurred in November 1999, and he was admitted to our hospital on 17 November. He became febrile, and complained of nasal congestion and cough on 3 December, at which time both the arterial blood gas analysis and the chest radiography were normal. Despite initiation of antibiotics, the symptoms persisted. Chest CT scans taken on 13 December demonstrated a patchy 'ground glass' appearance with areas of lung of normal appearance (Figure 4 ), suggesting the possibility of IP. We performed a bronchoscopy on 15 December. The findings of arterial blood gas analysis worsened (PaO 2 53 torr) on 18 December, and we initiated steroid pulse therapy as in case 1. Later, RSV was cultured from BALF, and pathological examination of the transbronchial lung biopsy specimens showed presence of atypical type II pneumocytes, compatible with viral infection. Also, RSV antigen was detected in sputum. We considered that RSV was the cause of the IP. The RSV IP rapidly worsened ( Figure 5 ) and the PCL progressed to involve a variety of organs. He therefore received DLI containing 3.5 × 10 7 /kg of CD3-positive cells on 28 December. Anti-RSV antibody was detected in the donor. Although the DLI seemed to have no effect against PCL, his respiratory status improved around 4 January (PaO 2 74 torr in room air). The arterial oxygen pressure reached 104 torr on 5 January. A nasal swab sample was negative for RSV antigen, and the lung lesions improved on chest CT scan on 13 January. Residual lesions, probably reflecting the fibrous changes, were observed in the left lobe, but the right lobe appeared normal ( Figure 6 ). The PCL progressed rapidly despite DLI. He died of septic shock on 22 January. Following his death, we obtained a BALF specimen. RSV antigen was not detected by EIA, 3 and RSV was not cultured from BALF. Figure 6 CT scans of the chest after DLI. Residual lesions, probably reflecting the fibrous changes, were observed in the left lobe, but the right light lobe appeared normal.
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Discussion
The best way to manage RSV infection following BMT is to prevent its occurrence, although aerosolized ribavirin with or without high-titer RSV-specific immunoglobulin has been used with some success in immunocompromised adult patients with RSV infection. 5, 6 However, previous phase I/II studies showed that neither intravenous nor aerosolized ribavirin had apparent benefit in either clearing RSV or reducing mortality. 7, 8 Although early use of aerosolized ribavirin may be effective for upper respiratory tract RSV infection, its efficacy is controversial in the event of lower respiratory tract infection. Furthermore, ribavirin is not approved for clinical use in Japan, and we could not use it for these patients.
At the onset of RSV pneumonia, we had little suspicion this was the diagnosis, and we initiated steroid pulse therapy in both patients. In case 1, we repeated it three times. Although the exact mechanism of RSV pneumonia remains unknown, additional factors are generally involved in the pathogenesis of viral infection besides viral cytopathology. Organ damage can be caused by both viral infection and host response to the infection. Thus, immune response modification has been frequently combined with anti-viral agents in the treatment of some viral diseases. Alwan et al 9 reported that CD4-positive cells cleared RSV with augmentation of RSV disease in a mouse model, and there is a report of successful use of steroids in the treatment of childhood RSV infection. 10 However, its effectiveness is controversial.
11 It is to be noted that the RSV pneumonia worsened during steroid pulse therapy in case 1. Surprisingly, the RSV antigen status remained positive 1 month after the onset of RSV pneumonia in this patient. These findings suggest that steroid therapy might suppress the anti-RSV immunity of the patient. Thus, eliminating RSV may be required in the treatment of RSV pneumonia rather than modulation of the immune reactions associated with RSV infection. In this regard, anti-RSV drugs are desirable for treating RSV pneumonia. However, no such drugs other than ribavirin have been developed, and small pilot studies on ribavirin have been disappointing. 7, 8 Probably, the most interesting finding was that RSV pneumonia improved after DLI in case 2. We transfused 3.5 × 10 7 /kg of CD3-positive cells to this patient to treat the relapsed PCL and blood gas analysis normalized on day 7 after DLI, although the relapsed PCL lesions showed no response to DLI. Because infiltration by PCL cells was not observed in lung biopsy specimens and no causative organism other than RSV was identified in BALF, it seems unlikely that any causative factor other than RSV contributed to the pathogenesis of IP in this patient. Considering that his immune status deteriorated because of the progression of PCL, DLI appeared to be effective for RSV pneumonia. To our knowledge, this is the first report of treatment of RSV pneumonia using DLI. DLI has been successfully used for some life-threatening viral infections including Epstein-Barr virus and adenovirus infections, after BMT, 12, 13 where it is postulated that adoptive transfer of virus-specific cytotoxic T lymphocytes (CTL) can reconstitute specific immunity and/or eliminate virus-infected cells. Furthermore, Ilan et al 14, 15 reported successful adop-tive transfer of immunity for hepatitis B virus using posttransplant DLI, and elimination of carrier state of hepatitis B by this treatment. RSV is a common respiratory virus, and the majority of healthy individuals have immunity against it, and indeed, the RSV-specific antibody status was positive in the donor. Thus, the donor lymphocytes transfused to the patient may have contained RSV-specific memory cells or CTL, which might be triggered to proliferate upon contact with RSV-infected cells and might ultimately eliminate them. However, we take care in interpreting the response to DLI in this patient. The accumulated evidence suggests that both humoral and cell-mediated mechanisms are involved in immunity to RSV, and induction of RSVspecific CTL has been shown to be protective for RSV infection in a mouse model. 9 However, there are some unclarified issues regarding the mechanism of immunity against RSV. For example, many healthy adults develop recurrent infections after initial infection. Because reinfection by RSV is usually mild in healthy individuals and it frequently evolves into severe acute lung injuries in immunocompromised patients, it is assumed that specific immunity to RSV develops after initial infection and is responsible for the mild illness seen upon reinfection.
However, we do not know to what extent recovery from RSV infection depends upon cell-mediated immunity, how transfused donor lymphocytes eliminate the infected cells, or what types of cells are essential for triggering anti-RSV immunity. It is not proven that the positive effect was truly mediated by DLI in this patient. However, this case suggests that DLI may be effective for RSV pneumonia, and further investigation is required.
In conclusion, we described the clinical courses of two patients who developed life-threatening RSV infection after BMT. Our experience showed that intensive immunosuppression using steroid pulse therapy is not indicated for RSV infection, and that there is a possibility that DLI is effective for eliminating RSV. DLI may be a promising therapeutic modality for RSV pneumonia.
